drugset / Trial / NCT05683964
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
Phase 0
Active not recruiting
9 enrolled
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen (PSMA) as detected by PET/CT scans for participants with recurrent prostate cancer. This study will measure PSMA levels using standard PET/CT scans and participants will receive standard-of-care androgen receptor antagonist monotherapy. The names of the treatment interventions involved in this study are: * Androgen receptor antagonist monotherapy. * PSMA PET/CT scan It is expected that about 15 people will take part in this research study. Participation in this research study is expected to last about 4 weeks.
Timeline
- Start
- 2023-01-19
- Primary completion
- 2025-09-18
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apalutamide | Small molecule | — | — |
| Subject | Darolutamide | Other / unclassified | — | — |
| Subject | Enzalutamide | Other / unclassified | — | — |